Latest news with #TomShea
Yahoo
6 days ago
- Business
- Yahoo
OneStream CEO highlights ‘deterministic' AI approach
This story was originally published on CFO Dive. To receive daily news and insights, subscribe to our free daily CFO Dive newsletter. Dive Brief: Enterprise software company OneStream will continue to build and refine AI solutions that help CFOs solve 'deterministic,' rather than 'subjective' problems, as it looks to execute on the strong performance it logged for its second quarter — where it reported a 26% increase in revenue year-over-year and a 281% jump in free cash flow, CEO and President Tom Shea told CFO Dive. The Birmingham, Mich.-based company's Q2 results show 'customers like that we have this platform that can deliver not only on the core financial capabilities that CFOs need, but also operational and AI [capabilities], and that journey is really resonating with CFOs,' Shea said in an interview. The business remains focused on developing AI solutions that will provide finance leaders with the transparent, trusted data they need from such technologies — rather than generating summaries or theories that require interpretation. 'We understand that in order for AI to be meaningful for CFOs, when CFOs are looking for deterministic solutions that have to be fact-based, we have to provide both the trust and the transparency, or there will be no adoption,' he said. Dive Insight: For the quarter ended June 30, OneStream reported total revenues of $147.6 million, while free cash flow hit $29.4 million compared to $7.7 million for the prior year period, according to its earnings results released Thursday. Net income reached $1.6 million, compared to an operating loss of $8.7 million for the prior year period. OneStream's bid to build out 'deterministic' AI tools comes as the finance chief's role has continued to evolve, Shea highlighted during the software provider's Q2 earnings call Friday. As CFOs take on more strategic and operational responsibilities, they are also examining how AI and similar technologies can be best used in the finance function. 'Having utilized outdated legacy financial systems for decades, CFOs are recognizing the crucial need for a platform to provide a single view into financial and operational data across the enterprise to effectively steer the business,' Shea said Friday according to a transcript, pointing to key business drivers for OneStream. The company is seeking to continue the growth shown in Q2 throughout the rest of the year, with an eye towards further strengthening profitability and cash flow, Shea told CFO Dive. For the fiscal year 2025, OneStream is targeting revenue between $586 million to $590 million, as well as net income per share of between $0.07 - $0.15, according to its earnings report. As it works towards that guidance, the company has continued to add new AI solutions to its 'SensibleAI' product suite, where it offers tools such as SensibleAI Forecast, which can aid financial leaders in scenario modeling and in identifying risk. In May, the company announced it would introduce agentic AI tools, including a 'deep analysis agent,' into the SensibleAI suite to help financial leaders address complex questions, CFO Dive previously reported. The agents remain in private preview and will be released in the next half year, Shea said. 'We're in the process right now validating that customers are getting that transparent response, that they can trust it,' Shea said of OneStream's agentic AI solutions. OneStream is one of several software providers which has moved to develop agentic AI solutions as finance leaders mull the potential benefits of such tools. A recent study by Salesforce found that on average, finance chiefs allocate 25% of their current AI budgets to agents, CFO Dive previously reported, while Salesforce CEO Marc Benioff previously announced plans to deploy one billion such agents by the end of the year. As OneStream continues to move forward with its agentic AI plans, the business is also weighing how current macroeconomic trends could impact its future strategy. OneStream is optimistic about its future growth, but the business is 'balancing' that positivity with 'some near-term prudence, just simply around the federal government,' Shea said, noting the company has a significant presence in the federal government. OneStream achieved Federal Risk and Authorization Management Program (FedRAMP) High authorization status in March, a designation that enables it to be used by federal agencies 'that require the highest level of security for the government's most sensitive, unclassified data in cloud computing environments,' according to a press release at the time. During its Q2 earnings call, 'we indicated that there's some uncertainty around the federal buying pattern in the near term, but we feel great about our long-term opportunity,' Shea said. Recommended Reading Zoom rebrands, aims to be known as 'AI-first' company 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
29-05-2025
- Business
- Yahoo
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast cancer and metastatic adenocarcinoma of the pancreas More than 168,000 people live with metastatic breast cancer in the U.S., with only one-third of patients surviving 5 years after diagnosis1 Bringing paclitaxel to market underscores Meitheal's commitment to meeting patients' needs through a sustainable, affordable supply of critical medicines CHICAGO, May 29, 2025--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ("HKF"), paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane®2, in the U.S. The 100mg/vial single-dose presentation of protein-bound paclitaxel for injectable suspension is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas, and locally advanced or metastatic non-small cell lung cancer. "Many patients living with difficult-to-treat cancers are faced with the unfortunate reality that the complex, life-saving treatments they need are too expensive or unavailable. At Meitheal, we're committed to closing this gap – we believe that today's launch is critical to ensuring that cancer patients get the medicines they need," said Tom Shea, Chief Executive Officer of Meitheal. "We're excited to bring this to market in the U.S. and provide patients and providers with a reliable supply of an effective cancer care treatment." The launch of paclitaxel increases Meitheal's portfolio of on-market generic injectables to 68 products, and builds on Meitheal's successful 12 product launches in 2024. In addition to paclitaxel, Meitheal is planning to launch 20 new products this year across its core therapeutic areas as it continues to identify gaps in the marketplace and evaluate opportunities to address the needs of both patients and providers. ABOUT PACLITAXELPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a type of chemotherapy, interfering with microtubules and causing cancerous cells to die. Paclitaxel is largely used for the treatment of metastatic breast cancer, and additional types of cancer. IMPORTANT SAFETY INFORMATIONINDICATIONSPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. SELECT IMPORTANT SAFETY INFORMATION WARNING: SEVERE MYELOSUPPRESSIONSee full prescribing information for complete boxed warning. Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/ for neutropenia, which may be severe and result in infection or frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound).CONTRAINDICATIONSNeutrophil counts of < 1,500 cells/mm3; and severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). WARNINGS AND PRECAUTIONSSensory neuropathy occurs frequently and may require dose reduction or treatment interruption. Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1,500 cells/mm3, then resume treatment at reduced dose levels. Pneumonitis occurred with the use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. Severe hypersensitivity reactions with fatal outcome have been reported. Do not rechallenge with this drug. Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin derived from human blood, which has a theoretical risk of viral transmission. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ADVERSE REACTIONSThe most common adverse reactions (≥ 20%) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea. DRUG INTERACTIONSUse caution when concomitantly administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4. USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. This is not the complete list of all the safety information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Please click to see the full Prescribing Information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). ABOUT MEITHEAL PHARMACEUTICALS, in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 60 U.S. FDA-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of April 2025, Meitheal, directly or through its partners, has 30 products in the research and development phase, 16 additional products planned for launch in 2025, and 23 products under review by the FDA. Meitheal's mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers' needs. Ranked #2 in 2024 on Crain's Fast 50 in Chicago, and in the top 100 of Crain's Best Places to Work in Chicago from 2022 to 2024, Meitheal emulates the traditional Irish guiding principle we are named for—working together toward a common goal, for the greater good. Learn more about who we are and what we do at ABOUT HONG KONG KING-FRIEND INDUSTRIAL COMPANY (HKF)Hong Kong King-Friend Industrial Company is a wholly owned subsidiary of NKF, founded in 2010. ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF)Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three U.S. FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence in the U.S., China, EU and across the world. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over U.S. $3.0 billion. 1 Susan G. Komen Foundation. February 21, 2025. Metastatic Breast Cancer. 2 Abraxane® is a registered trademark of Celgene. View source version on Contacts MEDIA Meitheal Pharmaceuticals, Spilman, VP of Corporate Strategy773 899 5910info@
Yahoo
29-05-2025
- Business
- Yahoo
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast cancer and metastatic adenocarcinoma of the pancreas More than 168,000 people live with metastatic breast cancer in the U.S., with only one-third of patients surviving 5 years after diagnosis1 Bringing paclitaxel to market underscores Meitheal's commitment to meeting patients' needs through a sustainable, affordable supply of critical medicines CHICAGO, May 29, 2025--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ("HKF"), paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane®2, in the U.S. The 100mg/vial single-dose presentation of protein-bound paclitaxel for injectable suspension is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas, and locally advanced or metastatic non-small cell lung cancer. "Many patients living with difficult-to-treat cancers are faced with the unfortunate reality that the complex, life-saving treatments they need are too expensive or unavailable. At Meitheal, we're committed to closing this gap – we believe that today's launch is critical to ensuring that cancer patients get the medicines they need," said Tom Shea, Chief Executive Officer of Meitheal. "We're excited to bring this to market in the U.S. and provide patients and providers with a reliable supply of an effective cancer care treatment." The launch of paclitaxel increases Meitheal's portfolio of on-market generic injectables to 68 products, and builds on Meitheal's successful 12 product launches in 2024. In addition to paclitaxel, Meitheal is planning to launch 20 new products this year across its core therapeutic areas as it continues to identify gaps in the marketplace and evaluate opportunities to address the needs of both patients and providers. ABOUT PACLITAXELPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a type of chemotherapy, interfering with microtubules and causing cancerous cells to die. Paclitaxel is largely used for the treatment of metastatic breast cancer, and additional types of cancer. IMPORTANT SAFETY INFORMATIONINDICATIONSPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. SELECT IMPORTANT SAFETY INFORMATION WARNING: SEVERE MYELOSUPPRESSIONSee full prescribing information for complete boxed warning. Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/ for neutropenia, which may be severe and result in infection or frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound).CONTRAINDICATIONSNeutrophil counts of < 1,500 cells/mm3; and severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). WARNINGS AND PRECAUTIONSSensory neuropathy occurs frequently and may require dose reduction or treatment interruption. Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1,500 cells/mm3, then resume treatment at reduced dose levels. Pneumonitis occurred with the use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. Severe hypersensitivity reactions with fatal outcome have been reported. Do not rechallenge with this drug. Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin derived from human blood, which has a theoretical risk of viral transmission. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ADVERSE REACTIONSThe most common adverse reactions (≥ 20%) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea. DRUG INTERACTIONSUse caution when concomitantly administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4. USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. This is not the complete list of all the safety information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Please click to see the full Prescribing Information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). ABOUT MEITHEAL PHARMACEUTICALS, in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 60 U.S. FDA-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of April 2025, Meitheal, directly or through its partners, has 30 products in the research and development phase, 16 additional products planned for launch in 2025, and 23 products under review by the FDA. Meitheal's mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers' needs. Ranked #2 in 2024 on Crain's Fast 50 in Chicago, and in the top 100 of Crain's Best Places to Work in Chicago from 2022 to 2024, Meitheal emulates the traditional Irish guiding principle we are named for—working together toward a common goal, for the greater good. Learn more about who we are and what we do at ABOUT HONG KONG KING-FRIEND INDUSTRIAL COMPANY (HKF)Hong Kong King-Friend Industrial Company is a wholly owned subsidiary of NKF, founded in 2010. ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF)Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three U.S. FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence in the U.S., China, EU and across the world. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over U.S. $3.0 billion. 1 Susan G. Komen Foundation. February 21, 2025. Metastatic Breast Cancer. 2 Abraxane® is a registered trademark of Celgene. View source version on Contacts MEDIA Meitheal Pharmaceuticals, Spilman, VP of Corporate Strategy773 899 5910info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
29-05-2025
- Business
- Business Wire
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ('Meitheal'), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ('HKF'), paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane ®2, in the U.S. The 100mg/vial single-dose presentation of protein-bound paclitaxel for injectable suspension is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas, and locally advanced or metastatic non-small cell lung cancer. 'Many patients living with difficult-to-treat cancers are faced with the unfortunate reality that the complex, life-saving treatments they need are too expensive or unavailable. At Meitheal, we're committed to closing this gap – we believe that today's launch is critical to ensuring that cancer patients get the medicines they need,' said Tom Shea, Chief Executive Officer of Meitheal. 'We're excited to bring this to market in the U.S. and provide patients and providers with a reliable supply of an effective cancer care treatment.' The launch of paclitaxel increases Meitheal's portfolio of on-market generic injectables to 68 products, and builds on Meitheal's successful 12 product launches in 2024. In addition to paclitaxel, Meitheal is planning to launch 20 new products this year across its core therapeutic areas as it continues to identify gaps in the marketplace and evaluate opportunities to address the needs of both patients and providers. ABOUT PACLITAXEL Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a type of chemotherapy, interfering with microtubules and causing cancerous cells to die. Paclitaxel is largely used for the treatment of metastatic breast cancer, and additional types of cancer. IMPORTANT SAFETY INFORMATION INDICATIONS Paclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. SELECT IMPORTANT SAFETY INFORMATION WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning. Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm3. Monitor for neutropenia, which may be severe and result in infection or sepsis. Perform frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound). CONTRAINDICATIONS Neutrophil counts of < 1,500 cells/mm3; and severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). WARNINGS AND PRECAUTIONS Sensory neuropathy occurs frequently and may require dose reduction or treatment interruption. Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1,500 cells/mm3, then resume treatment at reduced dose levels. Pneumonitis occurred with the use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. Severe hypersensitivity reactions with fatal outcome have been reported. Do not rechallenge with this drug. Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin derived from human blood, which has a theoretical risk of viral transmission. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS The most common adverse reactions (≥ 20%) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea. DRUG INTERACTIONS Use caution when concomitantly administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4. USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. This is not the complete list of all the safety information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Please click to see the full Prescribing Information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). ABOUT MEITHEAL PHARMACEUTICALS, INC. Founded in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 60 U.S. FDA-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of April 2025, Meitheal, directly or through its partners, has 30 products in the research and development phase, 16 additional products planned for launch in 2025, and 23 products under review by the FDA. Meitheal's mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers' needs. Ranked #2 in 2024 on Crain's Fast 50 in Chicago, and in the top 100 of Crain's Best Places to Work in Chicago from 2022 to 2024, Meitheal emulates the traditional Irish guiding principle we are named for—working together toward a common goal, for the greater good. Learn more about who we are and what we do at Hong Kong King-Friend Industrial Company is a wholly owned subsidiary of NKF, founded in 2010. ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF) Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three U.S. FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence in the U.S., China, EU and across the world. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over U.S. $3.0 billion. 1 Susan G. Komen Foundation. February 21, 2025. Metastatic Breast Cancer. 2 Abraxane ® is a registered trademark of Celgene.
Yahoo
14-05-2025
- Business
- Yahoo
OneStream shakes up finance software portfolio with AI agents
This story was originally published on CFO Dive. To receive daily news and insights, subscribe to our free daily CFO Dive newsletter. Finance software maker OneStream announced Tuesday that it was adding a series of new tools to its product portfolio, including 'artificial intelligence agents' capable of performing various kinds of data analysis for CFOs and their teams. Among other offerings, the company introduced a new 'deep analysis agent' designed to address highly complex financial questions after processing large volumes of documents. The agents are currently available to a limited set of customers in 'private preview' mode and could be fully rolled out later this year, according to OneStream CEO Tom Shea. 'We've pressure-tested the agents internally, and now we want to get feedback from the preview mode' before the full roll-out, he said in an interview. OneStream joins a growing list of tech companies that are developing AI agents — tools designed to perform workplace tasks in place of humans. Enterprise software giants such as Microsoft, Oracle, SAP and Workday started launching agents last year. Big Four accounting firms such as KPMG and Deloitte have jumped on the band wagon as well. OneStream intends to expand its agentic offerings over time and is 'committed' to making sure its agents are able to work with other ones, Shea said. The agents were debuted in Nashville on Tuesday at OneStream's annual customer conference. Other products unveiled at the event include 'SensibleAI Account Reconciliations,' which is designed to allow users to detect anomalies and flag risks — such as unusual adjustments or missing documentation — early in the close process. 'These solutions help finance leaders navigate uncertainty, identify risks sooner, run what-if scenarios, uncover more insights and drive confident decisions in a shorter amount of time,' the company said in a press release. Agentic technology is still in the early stages of development, and analysts have said it may be too soon for rapid adoption when it comes to sensitive business functions such as corporate finance. Among other potential challenges, an agent could leak sensitive data or the technology might 'hallucinate' and provide erroneous information. For its part, OneStream said in a Tuesday press release its AI agents operate 'within OneStream's security framework and offers full transparency into data sources and logic used, making them suitable for sensitive financial environments.' According to Shea, the company's deep analysis agent can respond to queries such as: 'For any customer that I've ever granted x amount of liability in their contract, please tell me the revenue that I've captured from that customer, and then give me an analysis of the risk-reward relationship between the liability that I have and the revenue that I capture for that customer.' The agent is able to perform 'much like a business analyst on your team that you might ask to do that type of work for you,' Shea said. The company also introduced an 'operations analyst agent' designed to provide on-demand access to operational and transactional data such as sales orders, as well as a 'search analyst agent' capable of searching unstructured data across enterprise documents. Sign in to access your portfolio
